Jun 10, 2021 / 06:10PM GMT
Madhu Sudhan Kumar - Goldman Sachs Group, Inc., Research Division - Research Analyst
Hey, everyone. Thank you for joining us here at the Goldman Sachs Global Healthcare Conference. I'm really, really excited to be joined by the whole team from Syndax Pharmaceuticals to give us an update on kind of an interesting first half of the year heading into hopefully even more interesting second half of the year.
Questions and Answers:
Madhu Sudhan Kumar - Goldman Sachs Group, Inc., Research Division - Research AnalystSo let's get started with the kind of big picture view. So team, if you could you then walk through kind of the current Syndax clinical pipeline focusing both on ongoing and kind of planned clinical trials given where you are today?
Briggs W. Morrison - Syndax Pharmaceuticals, Inc. - CEO & Director
Yes, Madhu. First, thanks so much for inviting us to participate. It's great to see you in your new assignment. We currently have 2 programs in clinical development, 5613 and axatilimab. 5613 is our Menin MLL
Trustpilot
